Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study

Table 2 Context of acute kidney injury and catecholamine dosages used during continuous venovenous hemodialysis treatment

	Minimum	25th percentile	Median	75th percentile	Maximum
Creatinine at hospital admission (mg/dl)	0.6	1.3	2.0	3.2	5.9
Urea at hospital admission (mg/dl)	3	27	45	87	138
Creatinine at ICU admission (mg/dl)	1.2	2.2	2.9	4.7	5.9
Urea at ICU admission (mg/dl)	16	34	52	91	135
24-hour urine production (ml) at ICU admission	0	100	400	1,000	2,900
Creatinine at first CVVHD (mg/dl)	0.8	2.4	3.4	5.2	46.0
Urea at first CVVHD (mg/dl)	29	50	70	116	181
Length of stay (days) at ICU until first CVVHD	0	2	4	8	20
Red blood cell units transfused before first CVVHD	0	0	2	4	14
Fresh frozen plasma units transfused before first CVVHD	0	0	4	10	26
Noradrenaline (μg/hour) at CVVHD start	0	100	300	900	30,000
Noradrenaline (μg/hour) at CVVHD end	0	0	300	900	30,000
Terlipressine (μg/hour) at CVVHD start	0	0	0	80	240
Terlipressine (μg/hour) at CVVHD end	0	0	0	40	240

Levels of creatinine (normal range 0.7 to 1.3 mg/dl) and urea (normal range 7 to 18 mg/dl) are depicted at hospital admission, at ICU admission and at the beginning of the first continuous venovenous hemodialysis (CVVHD) treatment. At ICU admission all 28 study patients had impaired kidney function, meeting at least acute kidney injury stage I criteria. Median length of stay in the ICU until the first CVVHD treatment was 4 days. Catecholamine dosages are presented (μg/hour) at the start and the ending of CVVHD treatment. At baseline, no catecholamine therapy was necessary in four out of the 43 CVVHD runs.

ISSN: 1364-8535